Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2025 | TRI-SCORE for Predicting Mortality After Tricuspid Valve TEER: The EURO TR Registry

Researchers analyzed a total of 1062 patients who underwent transcatheter edge-to-edge repair (TEER) for tricuspid regurgitation (TR).

Risk was classified using the TRI-SCORE: low (0–3 points), intermediate (4–5 points), and high (≥6 points).

Mortality was assessed at 30 days and two years.

The average age was 80 years, 48% of subjects were women, 63% had undergone prior hospitalization, the average TRI-SCORE was 6, the ejection fraction was 55%, and 27% had an RV pacemaker lead.

The cause of TR was secondary in 76.3% of cases, primary in 14.4%, and mixed in the remainder.

Read also: EuroPCR 2025 | One-Year Results of Pivotal Study in China with Dragonfly for Functional Mitral Regurgitation.

Thirty-day and two-year mortality rates were as follows:

  • Low risk population: 0% and 4.6%
  • Intermediate risk population: 1.9% y 13.9%
  • High risk population: 2.9% y 27.8%

Presented by Matthias Gröger during EuroPCR 2025 in Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

Más artículos de este Autor

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Artículos relacionados

Jornadas Guatemala 2026
Jornadas SOLACIspot_img

Artículos recientes

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

SOLACI Presented an Outstanding Scientific Session on Complex Coronary Lesions at EuroPCR 2026

The Latin American Society of Interventional Cardiology (SOLACI) had a prominent participation at EuroPCR 2026 through an institutional scientific session held on May 21...